Daiichi Sankyo bets on new cancer drugs to fuel future growth

🇯🇵 The Japan Times (JP) —

AI Summary

Daiichi Sankyo is focusing on expanding its oncology division, aiming to increase revenue to over ¥2.3 trillion by 2030. The company plans to become one of the top five players in the global oncology market by 2035.

The Japanese drugmaker aims to more than double oncology revenue to above ¥2.3 trillion by 2030 and become one of the world's top five oncology players by 2035.

Markets Deals pharmaceuticals oncology revenue market growth Japan

Read original source →